Thursday, June 4, 2026

Hawaii's Blue Cross Blue Shield plan, HMSA, denied nearly half of prior authorization requests in a recent period, according to state data. The 44.4% denial rate underscores the persistent administrative burden and financial risk for practices. For clinics dealing with HMSA or any BCBS plan, this reinforces the need for meticulous documentation and a robust internal review process before submission. While not a new policy change, it quantifies the denial environment. Ensure your staff are using the most current clinical guidelines and check payer portals for specific denial reason codes to streamline appeals.

athenahealth announced a major platform update with over 80 AI-native features designed to automate manual revenue cycle tasks. The enhancements target prior authorization, coding suggestions, denial prediction, and patient payment estimation. For practices using athenahealth, this represents a significant workflow shift; the vendor claims it can eliminate up to 70% of manual RCM work. Evaluate the rollout schedule for your instance and plan staff training. For practices on other platforms, this move signals increased competitive pressure for EHR vendors to deliver similar AI-driven automation, likely accelerating market-wide adoption of these tools in the next 12–18 months.

A Commonwealth Fund survey reveals 21% of insured adults experienced a coverage denial from their health plan in the past year. The data signals continued friction in the prior authorization and medical necessity review process, directly impacting patient access to prescribed treatments and tests. This high denial rate arrives as state and federal lawmakers increase scrutiny of insurer practices, including bills targeting prior authorization reform. While the survey does not detail specific service denials, it quantifies the scale of patient-provider disputes with payers.

A New York bill that would have prohibited health insurers and pharmacy benefit managers from reducing reimbursement to 340B-covered entities failed to pass the state Assembly. The legislation aimed to protect hospitals and clinics that rely on the federal drug discount program from payer policies that recoup savings by lowering payment rates. The bill's failure leaves 340B providers in the state vulnerable to continued contract terms that can erase the program's financial benefit, which is critical for funding care for low-income populations. This reflects ongoing national battles between 340B entities and payers over the program's economics.